Novartis
NVS
NVS
1,027 hedge funds and large institutions have $22.4B invested in Novartis in 2018 Q3 according to their latest regulatory filings, with 91 funds opening new positions, 359 increasing their positions, 368 reducing their positions, and 44 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
4% more funds holding
Funds holding: 986 → 1,027 (+41)
0.2% more ownership
Funds ownership: 11.2% → 11.4% (+0.2%)
2% less repeat investments, than reductions
Existing positions increased: 359 | Existing positions reduced: 368
Holders
1,027
Holding in Top 10
22
Calls
$89.4M
Puts
$63.6M
Top Buyers
| 1 | +$208M | |
| 2 | +$87.7M | |
| 3 | +$71.4M | |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$67.7M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$64M |
Top Sellers
| 1 | -$76.6M | |
| 2 | -$73.7M | |
| 3 | -$56.1M | |
| 4 |
Two Sigma Investments
New York
|
-$51.1M |
| 5 |
BBHC
Brown Brothers Harriman & Co
New York
|
-$46.3M |